Table 1.

Demographic and biologic characteristics of 24 adults with relapsed or refractory acute leukemia

AML (n = 21)ALL (n = 2)CML-BC (n = 1)
Male/female9/121/11/0
Age, median (range)56 (23–73)30, 6336
Previous cytarabine therapy1911
 2 g/m2/72 h infusion701
 High-dose cytarabinea700
Relapsed810
 No prior CR, median (range)2 (1–3)20
 Prior allogeneic SCT600
Refractoryb1311
 Prior regimens, median (range)2 (1–4)33
 Prior allogeneic SCT100
Secondary AML800
 MDS/MPDc600
 Treatment related200
Adverse genetics1311
 Single cytogenetics310
 Complex cytogenetics701
 FLT3 mutation300
  • aTwo to 3 g/m2 given every 12 hours for 6 to 12 doses as consolidation therapy or reinduction therapy.

  • bIncludes primary refractory and/or refractory to multiple therapies.

  • cMyelodysplastic syndrome/myeloproliferative disorder.